ERBB2 and cancer: ERBB2 gene amplification was most frequently identified in patients with gastric (21.4%; 6/28), colorectal (11.1%; 5/45), lung (3.9%; 9/231), and breast (3.2%; 1/31) cancers (Figure 3A, Supplementary Figure 2).